Posatex

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Posatex

Property	Description
Active Ingredients	Orbifloxacin, Mometasone Furoate, Posaconazole
Form	Viscous Otic Suspension (Ear Drops)
Pharmacological Class	Antibacterial, Antifungal, and Anti-inflammatory
Target Group	Canines (Dogs)
Origin	Synthetic, Triple-Action Combination

What Type of Medicine is Posatex Otic Suspension?

Posatex is a triple-action combination topical ear preparation developed specifically for veterinary use in dogs. It is classified as an antibacterial, antifungal, and anti-inflammatory drug, uniquely formulated to address the complex, multi-factorial nature of ear conditions. The product is a viscous Otic Suspension administered as ear drops via the auricular route. This preparation is entirely synthetic, combining three pharmacologically active compounds within a specific vehicle. Its formulation is supported by pharmacological studies confirming its intended use for complex otic conditions where microbial presence and inflammation coexist.

Core Composition: The Triple-Action Formula

The drug’s therapeutic strength is derived from three active ingredients: the antibiotic Orbifloxacin, the corticosteroid Mometasone Furoate, and the antifungal agent Posaconazole. Orbifloxacin is a synthetic, broad-spectrum fluoroquinolone that inhibits bacterial DNA synthesis. Mometasone Furoate is a potent corticosteroid known for its anti-inflammatory and anti-pruritic properties, rapidly reducing the swelling and irritation associated with the local condition. Posaconazole is an extended-spectrum triazole antifungal agent, which works by blocking the synthesis of ergosterol, a vital component of the fungal cell membrane. The formulation's distinct use of a mineral oil-based system contributes to its unique viscous property, ensuring prolonged contact time of the active ingredients with the ear canal lining.

What is the General Benefit of a Combination Ear Treatment?

The general benefit of this three-in-one formulation is the comprehensive control of the three factors primarily driving ear conditions: pathogenic bacteria, pathogenic fungi, and the resulting severe inflammation. By tackling microbial causes and inflammatory symptoms simultaneously, this preparation is designed to effectively manage the condition and quickly relieve associated discomfort. Combination topical treatments containing these three classes of drugs are often necessary to simplify treatment and achieve high rates of clinical improvement in veterinary patients.

Regulatory References

What side effects are possible with Posatex?

Possible side effects and safety information

The safety profile for this triple-action otic suspension is formally documented through governmental regulatory assessments, categorizing potential adverse effects primarily related to the application site and systemic effects associated with the corticosteroid component. The information below details the officially documented safety characteristics and adverse reactions.

Adverse Reactions by Frequency and System-Organ Class

Certain local reactions are classified by frequency based on regulatory standards. Pinnal erythema, or redness of the ear flap, is classified as a common adverse reaction, meaning it is observed in 1 to 10 animals per 100 treated. The potential for impaired hearing is categorized as uncommon (1 to 10 animals per 1,000 treated) and is noted to be usually temporary, occurring primarily in geriatric dogs.

Other local clinical signs noted in safety studies include aural pain, swelling, and heat at the site of administration. The systemic effects are linked to the active corticosteroid, Mometasone Furoate. Long-term or repeated use of topical otic corticosteroids has been associated with effects on the Endocrine System, specifically adrenocortical suppression and the development of iatrogenic hyperadrenocorticism.

Major Safety Constraints

The formulation is contraindicated in any canine with a known or suspected hypersensitivity to any active ingredient. A critical safety constraint concerns the integrity of the eardrum: the preparation is contraindicated for use in dogs with a known tympanic perforation (ruptured eardrum). This is essential because application with a perforated eardrum carries the risk of ototoxicity and the transmission of infection to the middle ear. Use must be immediately discontinued if hearing loss is observed during treatment.

Safety has not been established for use in dogs intended for breeding purposes, during pregnancy, or in lactating bitches. Additionally, the product must not be used in dogs less than four months of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Posatex Otic Suspension overdose focuses on findings from a safety study conducted on the target species (dogs) using an exaggerated dose.

Documented Overdose Presentations

In the animal safety study, administration of five times the recommended daily dose for a prolonged duration of 21 consecutive days resulted in a specific clinical manifestation. The most significant finding was a slight decrease in serum cortisol response following an adrenocorticotropic hormone (ACTH) stimulation test, which indicates a measurable, though slight, impact on adrenal function.

Prolonged or intensive use of topical corticosteroids, a component of the medication, is known to carry a potential risk for local and systemic effects, including suppression of the adrenal system.

Required Emergency Actions

The most explicit required action found in regulatory documents is a warning to immediately discontinue use of the product if hearing loss is observed during the course of treatment. This is a critical safety measure related to the ear application.

Connection to Overall Overdose Profile

The regulatory profile for overdose is based on intentionally high exposure in a safety study, not from typical clinical misuse or accidental ingestion. The data primarily highlight the potential for temporary adrenal system suppression due to the corticosteroid component when the product is used at a significant exaggeration of the prescribed dose and duration. The primary instruction for an urgent clinical event is the discontinuation of the product upon the observation of hearing loss.

Therapeutic Uses of Posatex

What Posatex Treats: Main Uses and Benefits

Posatex is relevant for the management of otitis externa in dogs, addressing complex clinical scenarios where inflammation coexists with microbial infection. This triple-action formula is commonly used for managing acute otitis externa and flare-ups of recurrent otitis externa. This therapeutic domain is applied across contexts where additional symptomatic support is needed due to the combination of bacterial pathogens, including susceptible Staphylococcus and Pseudomonas strains, and yeast (Malassezia pachydermatis).

The medication is commonly used to help with conditions characterized by periods of heightened symptoms and is relevant across domains involving inflammatory or irritative processes. It helps address symptom clusters related to local physical discomfort, such as significant redness (erythema), swelling (edema), and intense pruritus (itching). The symptomatic relief offered supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.

“The symptomatic relief is considered relevant for easing distress and supports patients during difficult episodes.”

Quick Fact: Supportive Relief for Pruritus and Inflammation

This medication is applied in scenarios where additional management of discomfort is required, as it provides support that helps ease the overall symptom burden of multi-factorial diseases and contributes to easing the overall symptom load during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Posatex — official regulatory information

Eligibility Scope

Classification	Population	Status Defined by Regulators
Populations for whom use is allowed	Dogs with acute otitis externa caused by susceptible yeast and bacteria.	Permitted under labeled conditions.
Populations for whom use is not recommended	Lactating dogs (bitches).	Not Recommended.
Populations for whom use is contraindicated	Dogs with known or suspected hypersensitivity to orbifloxacin, mometasone furoate, posaconazole, or excipients.	Contraindicated.

Age and Condition-Related Eligibility

Restriction Focus	Population	Status Defined by Regulators
Age-related rules	Animals less than 4 months of age.	Contraindicated.
Local Condition	Dogs with known tympanic membrane perforation (perforated eardrum).	Contraindicated.
Physiological Status	Pregnant dogs.	Contraindicated.
Use Not Established	Dogs used for breeding purposes.	Safe use has not been evaluated.

Resulting Eligibility Structure

Official regulatory documents define a restrictive eligibility profile based on specific physical, developmental, and physiological criteria. The medicine is contraindicated if the dog has a known perforated eardrum or is under four months old. Furthermore, use is contraindicated during pregnancy. The integrity of the tympanic membrane must be confirmed before use. Use is also prohibited in food-producing animals by federal law, and its safe use has not been established for breeding dogs.

What should I know about interactions with other medicines?

Posatex Interactions with other medicines and products

This section outlines the officially documented interaction profile for Posatex Otic Suspension (orbifloxacin, mometasone furoate, posaconazole), based strictly on government regulatory documents.

Documented Interaction Patterns

The regulatory labeling for Posatex identifies a limited number of interactions, primarily focusing on local administration safety and procedural product use. Regulatory bodies note that for interactions with other medicinal products, specific data on systemic effects are not available for this topical formulation.

Interaction-Related Restrictions and Cautions

1. Pharmacodynamic Risk with Other Ototoxic Agents

The U.S. Food and Drug Administration (FDA) prescribing information advises that this medication should not be used in dogs that are receiving other medications that are potentially toxic to the ears. This restriction is related to a risk of potential additive adverse effects on the ear.

2. Compatibility with Topical Cleaners

Regulatory documentation from the European Medicines Agency (EMA) specifies that compatibility with ear cleaners has not been demonstrated. Therefore, concurrent use with an ear cleaner that has a high pH is not recommended due to concerns about compatibility and potential alteration of the medication.

3. Systemic Interactions

There are no formally documented systemic drug-drug interactions (such as those involving metabolic enzymes or transporters) listed in the official regulatory documents for this topical veterinary product.

Mechanism of Action

Posatex is a combination veterinary otic suspension containing three distinct pharmacodynamic agents: orbifloxacin, posaconazole, and mometasone furoate. The formulation achieves high local concentrations within the ear canal following administration.

Orbifloxacin, a fluoroquinolone, exerts bactericidal action by interfering with bacterial DNA synthesis. It acts as an inhibitor of the enzymes DNA topoisomerase II (DNA-gyrase) and DNA topoisomerase IV, which are necessary for the supercoiling, replication, and repair of bacterial DNA. This disruption of genetic processes leads to rapid cell death in susceptible organisms.

Posaconazole, a triazole antifungal, functions as an inhibitor of the fungal enzyme lanosterol 14-demethylase (CYP51). This enzyme is crucial for the biosynthesis of ergosterol, a primary component of the fungal cell membrane. Inhibition of CYP51 blocks the conversion of lanosterol to ergosterol, leading to the accumulation of toxic sterol precursors within the fungal cell and subsequent structural and functional compromise of the cell membrane.

Mometasone furoate, a corticosteroid, acts by binding to intracellular glucocorticoid receptors. This binding modulates gene transcription, resulting in the inhibition of the synthesis of multiple pro-inflammatory mediators, including certain cytokines and eicosanoids. The resultant downstream cascade involves a reduction in local vascular dilation and capillary permeability, leading to system-level physiological modulation of localized inflammatory responses.

Dosage and Administration Information

Posatex Otic Suspension is administered exclusively via the topical auricular route, following the established dosing regimen. The administration protocol requires specific preparation steps. Before the initial instillation, the external ear canal must be meticulously cleaned and dried. The suspension must also be shaken well immediately prior to each use to ensure the active components are uniformly distributed.

The dosage is determined by the animal's weight and is administered once daily. Dogs weighing less than 30 pounds (approximately 15 kg) are to receive 4 drops per affected ear canal, while dogs weighing 30 pounds or more are to receive 8 drops per affected ear canal. Following the instillation of the prescribed drops, the base of the ear may be gently massaged to facilitate the penetration and distribution of the suspension within the canal.

This structured regimen specifies a finite treatment duration. The product is used for a period of seven consecutive days, and caution is advised against prolonged or repeated courses of use to maintain the integrity of the treatment plan. Furthermore, use in specific populations is constrained: safety has not been evaluated for breeding, pregnant, or lactating animals, establishing boundaries for the application of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Posatex

Research Evidence for Acute Otitis Externa

The clinical evaluation for Posatex primarily relies on Randomized Controlled Trials (RCTs) and Regulatory Clinical Field Efficacy Studies applied during the product's review process. These studies were used in research exploring how symptoms change over time and were conducted in canine patients diagnosed with acute inflammation of the outer ear canal, particularly where bacteria or yeast were suspected to be involved. Researchers in these trials monitored outcomes related to physical discomfort, evaluating how the ear condition evolved over a defined time interval.

Studies monitored various factors, including regulatory definitions of Clinical Success and the reduction of targeted pathogens like Malassezia pachydermatis yeast and specific bacterial strains. Findings indicate patterns related to these endpoints. Studies report how symptoms evolved in the observed populations for both the overall status of the ear and the presence of these microbes. This evidence contributes to understanding symptom patterns and the short-term changes observed in the trial populations.

Research Evidence for Flare-ups of Recurrent Otitis Externa

Posatex was also evaluated in studies examining patient-reported experiences during acute exacerbations of chronic or recurrent otitis externa. Research examined how symptoms evolved in the observed populations during episodes where symptoms become more noticeable. These studies often involved Comparative Evidence, where the combination treatment was monitored alongside other topical therapies.

Studies report how symptoms evolved in the observed populations, and research describes patterns related to symptom intensity or variability over the short-term study period. Heterogeneity in defining what constitutes a "recurrent flare-up" means that evidence quality varies across studies, and some subgroup findings are uncertain. The follow-up durations were limited, meaning there is limited information for long-term outcomes regarding how the use of the drug during a flare-up may influence the frequency or severity of future episodes.

Areas of Research Uncertainty and Gaps

The primary evidence related to the review of Posatex is derived from settings with varying symptom burdens and follows regulatory field trial standards. However, certainty remains low in several key areas. A key research limitation frame is the limited information for long-term outcomes and recurrence rates following treatment. Furthermore, evidence quality varies across studies concerning the precise clinical definition of a flare-up versus a new infection. Comparative evidence is lacking for certain uncommon or difficult-to-manage subgroups, and the sample sizes were modest in some supporting studies. Findings describe patterns observed in the studies but research provides context, not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Posatex (FAQ)

Q: What are the most common things people misunderstand about how Posatex should be used?

Regulatory documents describe specific requirements for use. For example, the external ear canal is required to be cleaned and dried before the first use, according to official administration conditions. The product labeling also notes that the suspension must be shaken well immediately before each use to ensure the active components are properly mixed. Furthermore, the official treatment course is intended for a short duration, specified as seven consecutive days.

Q: Is Posatex available as an over-the-counter medicine?

No, Posatex is not available as an over-the-counter medicine. According to official regulatory labeling, federal law restricts this drug to use by or on the order of a licensed veterinarian. It holds a Prescription Animal Drug classification.

Q: Are there different strengths or formulations of Posatex?

Official documentation indicates that Posatex is supplied as a single formulation: a viscous Otic Suspension, which is a liquid ear drop preparation. This formulation has one fixed concentration of the three active ingredients. While the product is available in different bottle sizes (e.g., 7.5 g or 30 g), the strength remains the same.

Q: Is Posatex used for different conditions in other countries?

Official indications provided by major regulatory bodies across different jurisdictions are generally consistent. The drug’s use is defined for the treatment of acute otitis externa (ear inflammation) and acute flare-ups of recurrent disease in dogs. This official use is for conditions where susceptible bacteria and fungi are implicated.

Q: What is the legal classification of Posatex (e.g., prescription-only)?

Posatex is officially classified as a Prescription Animal Drug (Rx). This classification means federal law restricts it to use by, or on the order of, a licensed veterinarian. It is not available for general sale.

Q: What if a user experiences a side effect not listed in the patient information?

The official documentation provides a formal mechanism for tracking all adverse reactions, including those not yet listed. Regulatory labels often provide a contact number (e.g., 1-800-224-5318 in the U.S.) for users to report suspected adverse events directly to the manufacturer for monitoring and review.

Q: Is Posatex a generic or a brand name drug?

Posatex is the brand name assigned to this combination medication, which is a proprietary product. It combines the three active ingredients: orbifloxacin, mometasone furoate, and posaconazole.

How should Posatex be stored and disposed of?

How to Store and Dispose of Posatex?

Posatex Otic Suspension must be stored within a mandatory temperature range of 2 C to 30 C (35.6 F to 86 F). It is required to keep the product in the original bottle and outer carton to maintain stability. The medicine must be kept out of the sight and reach of children.

Stability and Disposal

The product's stability after the first opening is limited; it must be used within 7 days for the 8.8 mL bottle or within 28 days for the 17.5 mL and 35.1 mL bottles. Unused or expired product must be disposed of in accordance with local requirements and is not to be discarded via wastewater systems, as per official regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.